Company Directory - Research & Development
Sana was founded with the long view – bringing together great people and the best technologies to deliver on the challenging promise of engineered cells as medicines.
Sangamo is a genomic medicine company that seeks to help millions of people who suffer from severe diseases for which today’s medicine can only offer symptom management at best. Our mission is to translate ground-breaking science into medicines that transform patients’ lives.
Seagen is a global biotechnology company dedicated to revolutionizing cancer care. We’re developing transformative therapies that make a meaningful difference in people’s lives. Seagen has led the way in novel cancer therapeutics for 20+ years.
Our mission is to create a new generation of smarter medicines that outmanoeuvre complex diseases in ways previously inconceivable. Senti is built on the shoulders of those who have come before. We believe in the power of knowledge and data to overcome any barriers to success.
Sernova Corp (TSX-V: SVA) is a clinical stage (US FDA; Health Canada) company, developing disruptive platform technologies to treat chronic diseases through a regenerative medicine approach.
SphingoTec develops and markets innovative in vitro diagnostic (IVD) tests for novel and proprietary blood-based protein biomarkers. These tests allow for the diagnosis, outcome prediction, and monitoring of acute medical conditions, such as septic shock, circulatory failure, acute heart failure and acute kidney injury.
SpyBiotech is a British biotechnology company with a novel vaccine platform technology to target infectious diseases, cancer and chronic diseases.
We are creating innovative psychiatric, neurological and respiratory therapies that help transform people's lives, while at the same time we are playing an increasingly active role in the future of global health.
We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families.
Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.
TOLREMO’s drug candidates aim to complement standard cancer therapies to offer better response rates, longer survival and an improved quality of life. In addition to combination therapies, we investigate our drug candidates for having efficacy as stand-alone agents in cancer indications of defined transcriptomes.
Originally founded in 1998 as an independent entity by Horst Lindhofer, we have assisted in the preclinical and clinical development of all Triomab® antibodies that are under development or received market approval, including that of Removab®, the first bispecific, trifunctional antibody on the market worldwide.
Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide.
Our Founder, Dr. Suzanne Ildstad, has spent much of her career researching and developing novel approaches to induce immune tolerance in organ transplant recipients, and to enable safer, allogeneic stem cell transplant procedures between mismatched donor-recipient pairs. Over the course of this 30 year journey, many additional dedicated scientists, clinicians and patients have helped us get to where we are today.
Theragnostics, a private biotech company based in UK and US, is developing innovative radiopharmaceuticals to improve cancer diagnosis and treatment.
Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies.
